companies / stipple-bio
Generated UTC · publication cutoff 2026-11-09
Insufficient cited evidence for a two-sentence summary.
verified=2026-04-29 json
| total_raised | 109,000,000109.0M | ○ |
|---|---|---|
| founded | null | |
| hq | Cambridge, United States | |
| industry | unknown | |
| stage | series-a |
Stipple Bio designs tumor-specific antibody therapies using an epitope-level 'pointillist' discovery approach. It serves oncology patients with cancers driven by surface targets that conventional antibody discovery misses. The stippling method finds subtle tumor-vs-healthy epitope differences instead of optimizing the most-abundant target.
No cited completed company acquisition recorded.
Dated disclosures. Customer relationships and classifications are historical; ARR is separate from revenue.
No cited disclosure recorded: named customer, disclosed revenue, ARR, count, B2B / B2C, sector, go-to-market.
No cited valuation with an explicit basis is recorded.
Historical post-money / actual annual or stated TTM revenue. Same currency; economic valuation date within 90 days of revenue period end, inclusive. No FX, ARR, annualized revenue, estimates or projections. Conflicts and ambiguous ties are withheld.
No qualifying pair recorded.
| date | type | amount | lead | src |
|---|---|---|---|---|
| 2026-04-01 | series-a | 100,000,000100.0M | null | ○ |
Nginx, WordPress 7.0, Astra 4.12.3, Google Hosted Libraries, jQuery Migrate 3.4.1, Elementor 4.0.9, Python, PHP, MySQL, jquery 2.1.1
| fact | status | src |
|---|---|---|
| Series A, $100.0M | attributed | ○ |
| existence | self-reported | WEB |
| description | self-reported | WEB |